Protective efficacy and safety of liver stage attenuated malaria parasites

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Kumar, Hirdesh ^a   Sattler, Julia Magdalena ^a   Singer, Mirko ^a   Heiss, Kirsten ^a,b   Reinig, Miriam ^a   Hammerschmidt Kamper, Christiane ^a   Heussler, Volker ^c   Mueller, Ann Kristin ^a,d   Frischknecht, Friedrich ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MalVa GmbH   (Germany)

^c Institute of Cell Biology   (Switzerland)

^d German Centre for Infectious Diseases (DZIF)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

ANIMAL; C57BL MOUSE; FEMALE; GENE DELETION; GENETICS; IMMUNOLOGY; LIVER; MALARIA; PARASITOLOGY; PLASMODIUM BERGHEI; SPOROZOITE; VACCINATION;

ANIMALS; FEMALE; GENE DELETION; LIVER; MALARIA; MALARIA VACCINES; MICE, INBRED C57BL; PLASMODIUM BERGHEI; SPOROZOITES; VACCINATION;

EID: 84973304440     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26824     Document Type: Article

References (43)

1. Nussenzweig, R. S., Vanderberg, J., Most, H. & Orton, C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216, 160-162 (1967).
2. Silvie, O. et al. Effects of irradiation on Plasmodium falciparum sporozoite hepatic development: implications for the design of preerythrocytic malaria vaccines. Parasite Immunol. 24, 221-223 (2002).
3. Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359-1365 (2013).
4. Hoffman, S. L. et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155-1164 (2002).
5. Beaudouin, R. L., Strome, C. P. A., Mitchell, F. & Tubergen, T. A. Plasmodium berghei: Immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp. Parasitol. 42, 1-5 (1977).
6. Belnoue, E. et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J. Immunol. 172, 2487-2495 (2004).
7. Roestenberg, M. et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468-477 (2009).
8. Friesen, J. et al. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci. Transl. Med. 2, 40ra49 (2010).
9. Mueller, A. K., Labaied, M., Kappe, S. H. & Matuschewski, K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433, 164-167 (2005).
10. Hafalla, J. C., Silvie, O. & Matuschewski, K. Cell biology and immunology of malaria. Immunol. Rev. 240, 297-316 (2011).
11. Borrmann, S. & Matuschewski, K. Protective immunity against malaria by 'natural immunization': a question of dose, parasite diversity, or both? Curr. Opin. Immunol. 23, 500-508 (2011).
12. Khan, S. M., Janse, C. J., Kappe, S. H. & Mikolajczak, S. A. Genetic engineering of attenuated malaria parasites for vaccination. Curr. Opin. Biotechnol. 23, 908-916 (2012).
13. Vaughan, A. M. et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell. Microbiol. 11, 506-520 (2009).
14. Rijpma, S. R. et al. Multidrug ABC transporters are essential for hepatic development of Plasmodium sporozoites. Cell. Microbiol., 18, 369-383 (2016).
15. Butler, N. S. et al. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9, 451-462 (2011).
16. Mueller, A. K. et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc. Natl. Acad. Sci. USA 102, 3022-3027 (2005).
17. Orr, R. Y., Philip, N. & Waters, A. P. Improved negative selection protocol for Plasmodium berghei in the rodent malarial model. Malar. J. 11, 103 (2012).
18. Ishino, T. et al. LISP1 is important for the egress of Plasmodium berghei parasites from liver cells. Cell. Microbiol. 11, 1329-1339 (2009).
19. Labaied, M. et al. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect. Immun. 75, 3758-3768 (2007).
20. VanBuskirk, K. M. et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc. Natl. Acad. Sci. USA 106, 13004-13009 (2009).
21. Mikolajczak, S. A. et al. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol. Ther. 22, 1707-1715 (2014).
22. van Schaijk, B. C. et al. A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites. Elife 3, e03582 (2014).
23. Carter, R. & Diggs, C. L. In Parasitic Protozoa Vol. 3 (ed J. P. Kreier) 359-465 (Academic Press, 1977).
24. Annoura, T. et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 30, 2662-2670 (2012).
25. Helm, S. et al. Identification and characterization of a liver stage-specific promoter region of the malaria parasite Plasmodium. PLoS ONE 5, e13653 (2010).
26. Orito, Y. et al. Liver-specific protein 2: a Plasmodium protein exported to the hepatocyte cytoplasm and required for merozoite formation. Mol. Microbiol. 87, 66-79 (2013).
27. Annoura, T. et al. Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development. FASEB J. 28, 2158-2170 (2014).
28. Tarun, A. S. et al. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8 + T cells. J. Infect. Dis. 196, 608-616 (2007).
29. Bafort, J., Timperman, G. & Delbar, T. Observations on tissue schizogony and sporogony of rodent malaria. Ann. Soc. Belges Med. Trop. Parasitol. Mycol. 48, 535-540 (1968).
30. Garnham, P. C. C., Landau, I. & Killick-Kendrick, R. Primary exo-erythrocytic schizonts of three rodent malaria parasites. Trans. R. Soc. Trop. Med. Hyg. 60, 3-4 (1966).
31. Spring, M. et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 31, 4975-4983 (2013).
32. Matuschewski, K. & Mueller, A. K. Vaccines against malaria-an update. FEBS J. 274, 4680-4687 (2007).
33. Van Dijk, M. R. et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc. Natl. Acad. Sci. USA 102, 12194-12199 (2005).
34. Aly, A. S. et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol. Microbiol. 69, 152-163 (2008).
35. Silvie, O., Goetz, K. & Matuschewski, K. A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. PLoS Pathog. 4, e1000086 (2008).
36. Jobe, O. et al. Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex class I-dependent interferon-γ -producing CD8 + T cells. J. Infect. Dis. 196, 599-607 (2007).
37. Yu, M. et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 4, 567-578 (2008).
38. Nagel, A. et al. A new approach to generate a safe double-attenuated Plasmodium liver stage vaccine. Int. J. Parasitol. 43, 503-514 (2013).
39. Singer, M. et al. Zinc finger nuclease-based double-strand breaks attenuate malaria parasites and reveal rare microhomology-mediated end joining. Genome Biol. 16, 249 (2015).
40. Janse, C. J., Ramesar, J. & Waters, A. P. High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite Plasmodium berghei. Nat. Protoc. 11, 346-356 (2006).
41. Hegge, S., Münter, S., Steinbüchel, M., Heiss, K., Engel, U., Matuschewski, K., & Frischknecht, F. Multi-step adhesion of Plasmodium sporozoites. FASEB J. 24, 2222-2234 (2010).
42. Tsuji, M., Mattei, D., Nussenzweig, R. S., Eichinger, D. & Zavala, F. Demonstration of heat-shock protein 70 in the sporozoite stage of malaria parasites. Parasitol. Res. 80, 16-21 (1994).
43. Burda, P. C. et al. A Plasmodium phospholipase is involved in disruption of the liver stage parasitophorous vacuole membrane. PLoS Pathog. 11, e1004760 (2015).